医疗事务声誉(美国)- 银屑病关节炎
市场调查报告书
商品编码
1773145

医疗事务声誉(美国)- 银屑病关节炎

Medical Affairs Reputations (US) - Psoriatic Arthritis

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告基于美国风湿病专家的定量回馈,检视了支持干癣性关节炎护理的医疗事务团队的绩效和声誉。报告探讨了医生如何与医疗事务专业人员互动,医生最重视哪些服务,以及他们对目前产品支援的满意度。报告还重点介绍了医生首选的沟通管道和互动频率、医生需求未满足的领域,以及各团队在关键绩效领域与竞争对手的比较。

关键问题

  • 医师与医疗事务团队的互动频率是增加还是减少?
  • 医师目前如何使用医疗事务团队提供的服务?
  • 医疗事务支援的哪些方面对医师最重要,他们对所提供的支持满意度如何?
  • 医师与医疗事务团队之间喜欢哪种类型的互动,互动频率如何?
  • 医疗事务团队在多大程度上满足了医师的需求?
  • 医疗事务团队在特定品牌的表现是低于还是高于预期?
  • 未来如何改善医疗事务服务以满足医师的需求?
  • 竞争对手的医疗事务团队在哪些方面最薄弱,哪些方面最强?

主要品牌

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

方法论:

FirstView 报告是基于对通过 LiMATM 遴选的医生进行的定量调查得出。 LiMATM 是全球最大的医生名录,拥有超过 300万名经过验证的医生。每位医生均根据严格的筛选标准精心挑选,以确保收集到的见解具有相关性、可靠性,并反映顶尖医疗专业人士的真实感受和经验。调查结果以易于理解的图表形式呈现,方便快速理解和分析资料。 FirstView Reports 凭藉 LiMATM 的广泛覆盖面和精准度,提供无与伦比的资料驱动洞察,指导策略规划,帮助在快速发展的医疗保健领域保持领先地位。

报告有何特别之处?

FirstWord Reports 是值得信赖的行业领导者,致力于製药业,为生物製药专业人士和决策者提供详细且可操作的洞察。深厚的行业知识使能够提供相关且有价值的洞察,帮助掌握新兴趋势,有效应对复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解,报告可提供所需的精确度和可靠性。独家获取其他地方无法获得的采访和资料,以及持续的市场监测,确保全面了解市场动态。报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法,使能够做出更明智的、资料驱动的决策,在快速变化的行业中保持竞争力。

简介目录

This report examines the performance and reputation of Medical Affairs teams supporting psoriatic arthritis therapies, based on quantitative feedback from US rheumatologists. It explores how physicians interact with Medical Affairs professionals, the services they find most valuable, and how satisfied they are with current support by product. The report also highlights preferred channels and frequency of engagement, areas where physician needs are unmet, and how individual teams compare to competitors in key performance areas.

Key Questions Answered:

  • How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • In what ways do physicians currently use the services provided by Medical Affairs teams?
  • What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • How successful are Medical Affairs teams at meeting physician needs?
  • Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.